LEGN News and Press, Legend Biotech Corporation

2024-06-25 07:20:00 ET Summary TimesSquare Capital Management, LLC is a fundamental research-oriented growth equity investment management firm specializing in growth equity strategies for institutional investors. TimesSquare uses a well-established team approach to growth investing th...

2024-06-21 09:35:00 ET Summary TimesSquare Capital Management, LLC is a fundamental research-oriented growth equity investment management firm specializing in growth equity strategies for institutional investors. TimesSquare uses a well-established team approach to growth investing th...

2024-06-20 17:01:11 ET USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 20,2024 – USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number o...

VANCOUVER – USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number of cancer cases in younger age groups than before. While researchers continue to search for a reason why this is happening, s...

2024-06-17 07:00:07 ET Asthika Goonewardene from Truist Financial issued a price target of $88.00 for LEGN on 2024-06-17 06:19:00. The adjusted price target was set to $88.00. At the time of the announcement, LEGN was trading at $42.45. The overall price target consensus...

2024-06-14 15:55:36 ET More on Bristol-Myers Squibb Company , Gilead Sciences, etc. Bristol-Myers Squibb: Move Investing Time Horizon To 2025, At Least Gilead Sciences, Inc. (GILD) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) Bristol-Myers...

2024-06-13 00:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-06-06 10:47:18 ET More on 2seventy bio 2seventy bio, Inc. (TSVT) Q1 2024 Earnings Call Transcript 2seventy Bio: Maximizing ABECMA's Potential To Fuel A Turnaround Bristol-Myers posts Q1 beat despite growth headwinds Bristol Myers, 2seventy bio's Abecma a...

2024-06-03 18:09:10 ET Read the full article on Seeking Alpha For further details see: J&J, Legend release promising results on Carvykti in earlier treatment line

First analysis of CARTITUDE-2 Cohort D study investigating CARVYKTI ® in multiple myeloma with suboptimal response after front-line ASCT featured in an oral presentation at the 2024 ASCO Annual Meeting show deep and durable responses with one-time infusion of CARVYKTI ® ...